drugset / Trial / NCT01645176

Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee

NCT01645176

Phase 2 Completed 21 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study of a combination therapy of hydroxychloroquine and atorvastatin is to learn about the effects in inflammation and pain in patients with Osteoarthritis of the knee. These medications are FDA approved and commercially available.

Timeline

Start
2012-05
Primary completion
2016-04
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 40 mg
Subject Hydroxychloroquine Small molecule 200 mg
Subject Hydroxychloroquine Small molecule 600 mg

Indications